PE20220767A1 - Derivados heterociclicos condensados - Google Patents
Derivados heterociclicos condensadosInfo
- Publication number
- PE20220767A1 PE20220767A1 PE2021001959A PE2021001959A PE20220767A1 PE 20220767 A1 PE20220767 A1 PE 20220767A1 PE 2021001959 A PE2021001959 A PE 2021001959A PE 2021001959 A PE2021001959 A PE 2021001959A PE 20220767 A1 PE20220767 A1 PE 20220767A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- heterocyclic condensed
- condensed derivatives
- derivatives
- preparing
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962853533P | 2019-05-28 | 2019-05-28 | |
| EP19176933 | 2019-05-28 | ||
| CN2020085720 | 2020-04-20 | ||
| PCT/US2020/034643 WO2020243135A1 (en) | 2019-05-28 | 2020-05-27 | Fused heterocyclic derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220767A1 true PE20220767A1 (es) | 2022-05-16 |
Family
ID=71741889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001959A PE20220767A1 (es) | 2019-05-28 | 2020-05-27 | Derivados heterociclicos condensados |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3976617B1 (https=) |
| JP (1) | JP2022535734A (https=) |
| KR (1) | KR20220012913A (https=) |
| CN (1) | CN113906028A (https=) |
| AU (1) | AU2020285718A1 (https=) |
| BR (1) | BR112021022889A8 (https=) |
| CA (1) | CA3138168A1 (https=) |
| CL (1) | CL2021003155A1 (https=) |
| CO (1) | CO2021016433A2 (https=) |
| CR (1) | CR20210666A (https=) |
| DO (1) | DOP2021000230A (https=) |
| IL (1) | IL288322A (https=) |
| JO (1) | JOP20210313A1 (https=) |
| MA (1) | MA56043A (https=) |
| MX (1) | MX2021014575A (https=) |
| PE (1) | PE20220767A1 (https=) |
| PH (1) | PH12021552974A1 (https=) |
| SG (1) | SG11202113167QA (https=) |
| WO (1) | WO2020243135A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022116999A1 (en) * | 2020-12-02 | 2022-06-09 | Janssen Sciences Ireland Unlimited Company | Fused heterocyclic derivatives and their use in the treatment of hbv infection |
| AR124222A1 (es) * | 2020-12-02 | 2023-03-01 | Janssen Sciences Ireland Unlimited Co | Derivados heterocíclicos condensados |
| WO2022116998A1 (en) * | 2020-12-02 | 2022-06-09 | Janssen Sciences Ireland Unlimited Company | Fused heterocyclic derivatives as hbv inhibitors |
| US20240279227A1 (en) * | 2021-06-02 | 2024-08-22 | Janssen Sciences Ireland Unlimited Company | Fused heterocyclic derivatives |
| AR126049A1 (es) | 2021-06-02 | 2023-09-06 | Janssen Sciences Ireland Unlimited Co | Derivados heterocíclicos condensados |
| WO2024114709A1 (en) * | 2022-12-01 | 2024-06-06 | Janssen Sciences Ireland Unlimited Company | A crystal form of a fused heterocycle derivative compound |
| WO2024140851A1 (zh) * | 2022-12-28 | 2024-07-04 | 上海维申医药有限公司 | 一类Toll样受体抑制剂及其制备和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2993174A1 (en) * | 2014-09-08 | 2016-03-09 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Pyrazolopyridine derivatives and their use in therapy |
| WO2016109684A2 (en) * | 2014-12-30 | 2016-07-07 | Novira Therapeutics, Inc. | Derivatives and methods of treating hepatitis b infections |
| AU2017290755B2 (en) * | 2016-06-29 | 2021-07-01 | Novira Therapeutics, Inc. | Diazepinone derivatives and their use in the treatment of hepatitis B infections |
| EP3478692B1 (en) * | 2016-06-29 | 2020-06-17 | Novira Therapeutics Inc. | Oxadiazepinone derivatives and their use in the treatment of hepatitis b infections |
| BR112021021564A2 (pt) * | 2019-04-30 | 2022-01-04 | Aicuris Gmbh & Co Kg | Indol-2-carboxamidas inovadoras ativas contra o vírus da hepatite b (hbv) |
-
2020
- 2020-05-27 WO PCT/US2020/034643 patent/WO2020243135A1/en not_active Ceased
- 2020-05-27 CR CR20210666A patent/CR20210666A/es unknown
- 2020-05-27 JP JP2021570274A patent/JP2022535734A/ja active Pending
- 2020-05-27 EP EP20744199.9A patent/EP3976617B1/en active Active
- 2020-05-27 CN CN202080039617.8A patent/CN113906028A/zh active Pending
- 2020-05-27 SG SG11202113167QA patent/SG11202113167QA/en unknown
- 2020-05-27 AU AU2020285718A patent/AU2020285718A1/en not_active Abandoned
- 2020-05-27 PE PE2021001959A patent/PE20220767A1/es unknown
- 2020-05-27 MX MX2021014575A patent/MX2021014575A/es unknown
- 2020-05-27 PH PH1/2021/552974A patent/PH12021552974A1/en unknown
- 2020-05-27 MA MA056043A patent/MA56043A/fr unknown
- 2020-05-27 BR BR112021022889A patent/BR112021022889A8/pt unknown
- 2020-05-27 KR KR1020217042210A patent/KR20220012913A/ko not_active Withdrawn
- 2020-05-27 CA CA3138168A patent/CA3138168A1/en active Pending
-
2021
- 2021-11-05 DO DO2021000230A patent/DOP2021000230A/es unknown
- 2021-11-23 IL IL288322A patent/IL288322A/en unknown
- 2021-11-25 JO JOP/2021/0313A patent/JOP20210313A1/ar unknown
- 2021-11-26 CL CL2021003155A patent/CL2021003155A1/es unknown
- 2021-12-01 CO CONC2021/0016433A patent/CO2021016433A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2021000230A (es) | 2022-05-31 |
| BR112021022889A2 (pt) | 2022-01-04 |
| MA56043A (fr) | 2022-04-06 |
| CL2021003155A1 (es) | 2022-07-22 |
| WO2020243135A1 (en) | 2020-12-03 |
| SG11202113167QA (en) | 2021-12-30 |
| CA3138168A1 (en) | 2020-12-03 |
| PH12021552974A1 (en) | 2022-07-11 |
| IL288322A (en) | 2022-01-01 |
| JP2022535734A (ja) | 2022-08-10 |
| CN113906028A (zh) | 2022-01-07 |
| KR20220012913A (ko) | 2022-02-04 |
| JOP20210313A1 (ar) | 2021-11-25 |
| BR112021022889A8 (pt) | 2024-03-05 |
| MX2021014575A (es) | 2022-05-24 |
| CR20210666A (es) | 2022-03-11 |
| CO2021016433A2 (es) | 2021-12-10 |
| EP3976617B1 (en) | 2025-04-23 |
| EP3976617A1 (en) | 2022-04-06 |
| AU2020285718A1 (en) | 2022-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220767A1 (es) | Derivados heterociclicos condensados | |
| JOP20230272A1 (ar) | مركبات تثبيط rip1 وطرق لتحضير واستخدامها | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| DOP2019000117A (es) | Nuevos derivados de quinolina | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| CL2017001798A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas. | |
| SV2018005610A (es) | Derivados de oxopiridina sustituidos | |
| BR112018070602A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio | |
| BR112017000550A2 (pt) | compostos antiproliferativos e métodos de uso dos mesmos | |
| MX2017008720A (es) | Derivados y metodos para tratamiento de las infecciones por hepatitis b. | |
| UY37831A (es) | Nuevos derivados de quinolina | |
| MX2017014645A (es) | Profarmacos de alvocidib que tienen una biodisponibilidad aumentada. | |
| BR112018072168A2 (pt) | compostos derivados da pirimidina como inibidores da quinase jak | |
| CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
| MX373703B (es) | Derivados de azepano y metodos para tratar infecciones por hepatitis b. | |
| CO2021002977A2 (es) | Dimetilaminoazetidinaminas como inhibidores de jak | |
| MX393586B (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue | |
| UY37646A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| UY31673A1 (es) | "derivados heterocíclicos de urea y métodos de uso de los mismos-211" | |
| CO2018008421A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CL2020002891A1 (es) | Nuevos derivados de quinolina | |
| BR112019000453A2 (pt) | combinação de ceftibuteno e ácido clavulânico para uso no tratamento de infecções bacterianas | |
| UY36217A (es) | Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso. | |
| MX395175B (es) | Compuesto heterocíclico aromático nitrogenado, método de preparación para el mismo, composición farmacéutica del mismo, y aplicación del mismo. | |
| UY39550A (es) | Derivados heterocíclicos condensados |